About BachemGroup
BachemGroup is a company based in Bubendorf (Switzerland) founded in 1971. The company has 2,210 employees as of December 31, 2024. BachemGroup offers products and services including Catalog Peptides, Custom Peptide Synthesis, and Oligonucleotide NCEs. BachemGroup operates in a competitive market with competitors including Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma, among others.
- Headquarter Bubendorf, Switzerland
- Employees 2210 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bachem Holding Ag Class B
-
Annual Revenue
$668.09 M (USD)4.84as on Dec 31, 2024
-
Net Profit
$132.73 M (USD)7.5as on Dec 31, 2024
-
EBITDA
$193.4 M (USD)5.6as on Dec 31, 2024
-
Latest Funding Round
Not available
- Investors
-
Employee Count
2210
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of BachemGroup
BachemGroup is a publicly listed company on the SIX with ticker symbol BANB in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of BachemGroup
BachemGroup offers a comprehensive portfolio of products and services, including Catalog Peptides, Custom Peptide Synthesis, and Oligonucleotide NCEs.
Ready-to-deliver peptides for research and development purposes.
Tailored production of peptides for specific client needs.
Development and manufacturing of oligonucleotide new chemical entities.
People of BachemGroup
Unlock access to complete
Unlock access to complete
Funding Insights of BachemGroup
Investors in BachemGroup
BachemGroup has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for BachemGroup
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BachemGroup
Investment portfolio details for BachemGroup
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - BachemGroup
Detailed financials for BachemGroup
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bachemgroup Comparisons
Peer comparison for BachemGroup
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BachemGroup
BachemGroup operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Integrated CDMO services for biopharma R&D and manufacturing are offered.
|
|
| Locked | Locked | Locked |
APIs manufacturing and formulation services are provided in therapeutic segments.
|
|
| Locked | Locked | Locked |
APIs and enzymes are manufactured through fermentation by the CDMO.
|
|
| Locked | Locked | Locked |
APIs and finished products are developed and manufactured.
|
|
| Locked | Locked | Locked |
Generic biocatalytic solutions are provided for pharmaceutical applications.
|
|
| Locked | Locked | Locked |
APIs and peptides are developed and manufactured by Asymchem.
|
Detailed competitors of BachemGroup
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bachemgroup
Complete news archive for BachemGroup
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BachemGroup
BachemGroup was founded in 1971 and raised its 1st funding round 43 years after it was founded.
BachemGroup is headquartered in Bubendorf, Switzerland. It is registered at Bubendorf, Basel-landschaft, Switzerland.
Thomas Fruh is the current CEO of BachemGroup.
As of Dec 31, 2024, the latest employee count at BachemGroup is 2,210.
Annual revenue of BachemGroup is $668.09M as on Dec 31, 2024.
Bachem is a listed technology-based company focused on peptide chemistry. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom synthesis for research labs completes their service portfolio. It claims to have 40 years of experience in peptide research and know-how in peptide chemistry and organic synthesis. Bachems GMP manufacturing facilities are located in Switzerland and the United States and are approved by the FDA and local authorities. In addition, the company is also, involved in more than 200 cGMP projects targeting New Chemical Entities. It is headquartered in Switzerland with subsidiaries in Europe and the US.
BachemGroup's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Almac Group.
BachemGroup offers Catalog Peptides, Custom Peptide Synthesis, and Oligonucleotide NCEs.
Yes, BachemGroup is publicly traded on SIX under the ticker symbol BANB.
BachemGroup has 1 investor. Key investors include European Union.
The ticker symbol of BachemGroup is BANB on SIX.